RECURSION PHARMACEUTICALS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 3.47 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 3.47M shares, a 74.41% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 5.50M shares, a 68.12% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 14.51M shares, a 15.47% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 13.56M shares, a 6.71% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 14.81M shares, a 11.98% decline from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 16.82M shares, a 54.04% increase from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 10.92M shares, a 0.41% decline from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 10.97M shares, a 78.13% decline from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.47M shares 10-Q · filed 2026-08-05 | 3.76M shares 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | 5.50M shares 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | 14.81M shares 10-K · filed 2026-02-25 | |||
| 2025-09-30 | 14.51M shares 10-Q · filed 2025-11-05 | 15.70M shares 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | 13.56M shares 10-Q · filed 2026-08-05 | 15.95M shares 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | 17.27M shares 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | 16.82M shares 10-K · filed 2026-02-25 | |||
| 2024-09-30 | 12.56M shares 10-Q · filed 2025-11-05 | 14.79M shares 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | 14.54M shares 10-Q · filed 2025-08-05 | 15.93M shares 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | 16.30M shares 10-Q · filed 2025-05-05 | |||
| 2023-12-31 | 10.92M shares 10-K · filed 2026-02-25 | |||
| 2023-09-30 | 12.16M shares 10-Q · filed 2024-11-06 | 9.02M shares 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | 7.72M shares 10-Q · filed 2024-08-08 | 8.00M shares 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | 8.53M shares 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 10.97M shares 10-K · filed 2025-02-28 | |||
| 2022-09-30 | 12.57M shares 10-Q · filed 2022-11-08 | 10.85M shares 10-Q · filed 2022-11-08 | ||
| 2022-06-30 | 8.23M shares 10-Q · filed 2022-08-09 | 10.48M shares 10-Q · filed 2022-08-09 | ||
| 2022-03-31 | 12.09M shares 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | 50.15M shares 10-K · filed 2024-02-29 | |||
| 2021-09-30 | 16.97M shares 10-Q · filed 2022-11-08 | 62.02M shares 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | 42.71M shares 10-Q · filed 2022-08-09 | 85.64M shares 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | 120.43M shares 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | 94.44M shares 10-K · filed 2023-02-27 | |||
| 2020-09-30 | 93.53M shares 10-Q · filed 2021-11-10 | 86.16M shares 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | 83.45M shares 10-Q · filed 2021-08-13 | 82.97M shares 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | 82.19M shares 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | 87.52M shares 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |